<DOC>
	<DOCNO>NCT01839045</DOCNO>
	<brief_summary>The major purpose study evaluate laboratory developed test measure multiple breast cancer-specific biomarker protein blood sample . The biomarker result along personal medical profile evaluate determine risk presence malignancy breast compare breast evaluation assessment conduct physician .</brief_summary>
	<brief_title>Breast Cancer Biomarker Sample Collection dtectDx Assay Verification</brief_title>
	<detailed_description>As part study , 35 mL 2 1/2 tablespoon blood drawn arm study visit . This study 2 visit . Visit 1 take 1 hour . Visit 2 follow visit 6 month take 1 hour . Visit 1- Screening Blood Collection : The following procedure do clinical research facility : - The study doctor and/or study staff explain study study procedure . - You ask review , sign date inform consent procedure do . - The study doctor and/or study staff ask question health status medical history record information . - 35 mL 2 ½ tablespoon blood collect arm . - The sample label name unique identification code , mean give number link . Visit 2 - Follow : If diagnose cancer visit 1 visit 2 , require complete visit 2 . If diagnose LCIS DCIS , request return visit 2 . Otherwise return center visit 2 . The following procedure perform : - You follow-up breast evaluation perform . Your follow-up breast evaluation may occur prior Visit 2 perform different facility may perform study visit . - The study doctor and/or study staff ass health medical history . - 35 mL 2 1/2 tablespoon blood collect arm . - The sample label name unique identification code , mean give number link . Your blood sample send study Sponsor , Provista Diagnostics , Inc. test . The test result report back study doctor use determine change treatment . This test do addition routine test study doctor performs . You receive result test . Up 350 subject take part study . Patients enrol one seven site .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Adult woman 25 year age 50 year age Breast evaluation result ACR BIRADS® Category 3 4 imaging physician clinical radiological evaluation Study visit blood collection within 3 week ( 21 day ) ACR BIRADS assessment Patient agree return diagnostic followup blood collection 6 month unless positive cancer diagnosis make study visit 1 2 . Individuals diagnose LCIS DCIS agree return visit 2 Samples collect IRB approval Informed Consent Testing perform IRB approval waiver ( applicable ) Adults 50 year age old 25 year age Final breast evaluation result ACR BIRADS Category 3 4 Subjects breast biopsy perform time prior study visit Samples collect IRB approval Informed Consent Testing perform IRB approval waiver ( applicable ) Prior breast cancer diagnosis .</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Woman</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Cancer</keyword>
	<keyword>Mammogram</keyword>
	<keyword>Ultrasound</keyword>
	<keyword>Imaging</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>ACR BI RAD Category 3</keyword>
	<keyword>ACR BI RAD Category 4</keyword>
</DOC>